Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia? Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with ...
Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial First, patient-level correlation was confirmed using ...
MedPage Today on MSN
Recent Developments in Chronic Lymphocytic Leukemia
Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...
Cervical cancer is among the most common malignancies affecting women worldwide. In 2020 alone, approximately 600,000 women were diagnosed with this disease, and over 314,000 died from it. In 99% of ...
Lymphocyte-depleted Hodgkin’s lymphoma (LDHL) is a rare subtype of Hodgkin’s lymphoma, a cancer that develops in the lymphatic system. Hodgkin’s lymphoma (HL) is an uncommon cancer of the lymphatic ...
Blood-based biomarkers, including neutrophil-to-lymphocyte ratio and circulating tumor DNA, may improve treatment response ...
New EORTC guidelines establish meaningful change thresholds for symptom burden, physical condition/fatigue, and worries/fears in R/R CLL or SLL patients. Thresholds help identify significant ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果